학술논문

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Document Type
Academic Journal
Author
Fendler A; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Shepherd STC; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Au L; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Wilkinson KA; Tuberculosis Laboratory, the Francis Crick Institute, London, UK.; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory, Cape Town, Republic of South Africa.; Wu M; High Throughput Screening Laboratory, the Francis Crick Institute, London, UK.; Byrne F; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Cerrone M; Tuberculosis Laboratory, the Francis Crick Institute, London, UK.; Department of Infectious Disease, Imperial College London, London, UK.; Schmitt AM; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Joharatnam-Hogan N; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Shum B; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Tippu Z; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Rzeniewicz K; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Boos LA; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Harvey R; Worldwide Influenza Centre, the Francis Crick Institute, London, UK.; Carlyle E; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Edmonds K; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Del Rosario L; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Sarker S; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Lingard K; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Mangwende M; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Holt L; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Ahmod H; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Korteweg J; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Foley T; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Bazin J; Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Gordon W; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Barber T; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Emslie-Henry A; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Xie W; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Gerard CL; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Deng D; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.; Wall EC; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, UK.; Structural Biology of Disease Processes Laboratory, the Francis Crick Institute, London, UK.; Agua-Doce A; Flow Cytometry Scientific Technology Platform, the Francis Crick Institute, London, UK.; Namjou S; Safety, Health & Sustainability, the Francis Crick Institute, London, UK.; Caidan S; Safety, Health & Sustainability, the Francis Crick Institute, London, UK.; Gavrielides M; Scientific Computing Scientific Technology Platform, the Francis Crick Institute, London, UK.; MacRae JI; Metabolomics Scientific Technology Platform, the Francis Crick Institute, London, UK.; Kelly G; Department of Bioinformatics and Biostatistics, the Francis Crick Institute, London, UK.; Peat K; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Kelly D; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Murra A; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Kelly K; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; O'Flaherty M; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Dowdie L; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Ash N; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Gronthoud F; Department of Pathology, the Royal Marsden NHS Foundation Trust, London, UK.; Shea RL; Department of Pathology, the Royal Marsden NHS Foundation Trust, London, UK.; Translational Cancer Biochemistry Laboratory, the Institute of Cancer Research, London, UK.; Gardner G; Department of Pathology, the Royal Marsden NHS Foundation Trust, London, UK.; Murray D; Department of Pathology, the Royal Marsden NHS Foundation Trust, London, UK.; Kinnaird F; Clinical Trials Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Cui W; Lung Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Pascual J; Breast Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Rodney S; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Mencel J; Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Curtis O; Lung Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Stephenson C; Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Robinson A; Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Oza B; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Farag S; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Leslie I; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Rogiers A; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Iyengar S; Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Ethell M; Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Messiou C; Department of Radiology, the Royal Marsden NHS Foundation Trust, London, UK.; Cunningham D; Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Chau I; Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Starling N; Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Turner N; Breast Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Welsh L; Neuro-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; van As N; Clinical Oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Jones RL; Sarcoma Unit, the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.; Droney J; Palliative Medicine, the Royal Marsden NHS Foundation Trust, London, UK.; Banerjee S; Gynaecology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Tatham KC; Anaesthetics, Perioperative Medicine and Pain Department, the Royal Marsden NHS Foundation Trust, London, UK.; O'Brien M; Lung Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Harrington K; Head and Neck Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; Bhide S; Head and Neck Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; Okines A; Breast Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Acute Oncology Service, the Royal Marsden NHS Foundation Trust, London, UK.; Reid A; Uro-oncology Unit, the Royal Marsden NHS Foundation Trust, Surrey, UK.; Young K; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Furness AJS; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Pickering L; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Swanton C; Cancer Evolution and Genome Instability Laboratory, the Francis Crick Institute, London, UK.; University College London Cancer Institute, London, UK.; Gandhi S; Neurodegeneration Biology Laboratory, the Francis Crick Institute, London, UK.; UCL Queen Square Institute of Neurology, London, UK.; Gamblin S; Structural Biology of Disease Processes Laboratory, the Francis Crick Institute, London, UK.; Bauer DLV; RNA Virus Replication Laboratory, the Francis Crick Institute, London, UK.; Kassiotis G; Retroviral Immunology Laboratory, the Francis Crick Institute, London, UK.; Kumar S; Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Yousaf N; Lung Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Acute Oncology Service, the Royal Marsden NHS Foundation Trust, London, UK.; Jhanji S; Anaesthetics, Perioperative Medicine and Pain Department, the Royal Marsden NHS Foundation Trust, London, UK.; Nicholson E; Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.; Howell M; High Throughput Screening Laboratory, the Francis Crick Institute, London, UK.; Walker S; Anaesthetics, Perioperative Medicine and Pain Department, the Royal Marsden NHS Foundation Trust, London, UK.; Wilkinson RJ; Tuberculosis Laboratory, the Francis Crick Institute, London, UK.; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory, Cape Town, Republic of South Africa.; Department of Infectious Disease, Imperial College London, London, UK.; Larkin J; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.; Turajlic S; Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.; Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK. samra.turajlic@crick.ac.uk.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
(© 2021. The Author(s).)